Targeting autoimmune pulmonary alveolar proteinosis with GM-CSF: insights from clinical trials and emerging therapies [0.03%]
GM-CSF在自身免疫性肺泡蛋白沉积症中作用机制及治疗进展：临床试验与新兴疗法带来的启示
Margaret Higgins,Niamh Boyle,Cormac McCarthy
Margaret Higgins
Introduction: Pulmonary alveolar proteinosis (PAP) is a rare lung disease caused by impaired surfactant clearance resulting in lipoproteinaceous material accumulation in the alveoli often causing progressive dyspnea and r...
Maram E Abdalla Elsayed,Robert E MacLaren
Maram E Abdalla Elsayed
Targeting the tumor microenvironment in genitourinary cancers: current progress and future directions in prostate cancer [0.03%]
泌尿生殖系统肿瘤微环境的分子靶向治疗：前列腺癌研究的最新进展和未来方向
Susan F Slovin
Susan F Slovin
Introduction: Prostate cancer is no longer considered a 'cold' tumor; several novel immune platforms are now capable of overcoming obstructive cellular and soluble impediments within the tumor microenvironment (TME) thus ...
Successful dose reduction of dupilumab in pediatric patients with atopic dermatitis in daily practice: results from the BioDay registry [0.03%]
REAL-WORLD DUPLICATIONAB剂量减少在儿童患者中的成功案例：来自BioDay登记处的结果
Florence Vroman,Octavian I Bacoş-Cosma,Lisa C de Krosse et al.
Florence Vroman et al.
Background: Data on individualized dosing regimens for dupilumab in pediatric atopic dermatitis (AD) are lacking. This study evaluated dose reduction of dupilumab in a pediatric population in daily practice. ...
Potential of new BCMA-targeting therapies in overcoming resistance in multiple myeloma [0.03%]
靶向BCMA的新型疗法在克服多发性骨髓瘤耐药性方面的潜力
Manraj Singh Sra,Shaji Kumar
Manraj Singh Sra
Introduction: B-cell maturation antigen is an important therapeutic target in multiple myeloma. Several chimeric antigen receptor T-cell (CAR-T) products, bispecific T-cell engagers, and antibody-drug conjugates targeting...
Treating Castleman disease: insights into the use and efficacy of monoclonal antibodies [0.03%]
Castleman病的治疗：单克隆抗体的应用和疗效分析
Yoshito Nishimura,Thomas Habermann,Angela Dispenzieri et al.
Yoshito Nishimura et al.
Introduction: Castleman disease (CD) is a rare, heterogeneous group of disorders driven by dysregulated cytokine signaling, particularly interleukin‑6 (IL‑6). Over the past decade, monoclonal antibody (mAb) targeting IL...
Biologic modulation of ineffective erythropoiesis in thalassemia: mechanisms, clinical practice, and future targets [0.03%]
β地中海贫血无效红细胞生成的生物调控：机制、临床实践及未来靶点
Ali T Taher,Mohammad Hassan Hodroj,Maria Domenica Cappellini
Ali T Taher
TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort [0.03%]
儿童关节炎相关性葡萄膜炎长期管理中使用肿瘤坏死因子抑制剂的ITHACA队列的真实世界数据
Achille Marino,Dariush Khaleghi Hashemian,Claudia Iannone et al.
Achille Marino et al.
Objectives: We assess prescription patterns and describe the long-term real-life effectiveness of different TNF inhibitors (TNFis) in juvenile idiopathic arthritis-related uveitis (JIA-U). ...
Giorgio Ciprandi,Maria Angela Tosca
Giorgio Ciprandi
Introduction: Over the past two decades, targeted biological therapies have profoundly transformed the management of type 2 (T2) inflammatory diseases, including severe asthma, atopic dermatitis, chronic rhinosinusitis wi...
Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis [0.03%]
成人继发性噬血细胞综合征生物治疗的现状及展望
Aishwarya Ghonge,Victor M Samperio,Moza Hamoud et al.
Aishwarya Ghonge et al.
Introduction: Adult secondary hemophagocytic lymphohistiocytosis (asHLH) is a fulminant hyperinflammatory condition triggered by cancers, infections, autoimmune conditions or drugs. The hallmark of its pathogenesis involv...